155 related articles for article (PubMed ID: 31565482)
1. Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57
Li W; Bi C; Han Y; Tian T; Wang X; Bao H; Xu X; Zhang X; Liu L; Zhang W; Gao H; Wang H; Zhang H; Meng B; Wang X; Fu K
Cancer Biol Med; 2019 Aug; 16(3):530-541. PubMed ID: 31565482
[TBL] [Abstract][Full Text] [Related]
2. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of EZH1/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1.
Ito J; Yamagata K; Shinohara H; Shima Y; Katsumoto T; Aikawa Y; Kitabayashi I
Int J Hematol; 2023 Jan; 117(1):78-89. PubMed ID: 36280659
[TBL] [Abstract][Full Text] [Related]
4. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
5. MicroRNA-20a Suppresses Tumor Proliferation and Metastasis in Hepatocellular Carcinoma by Directly Targeting EZH1.
Zhang Q; Deng X; Tang X; You Y; Mei M; Liu D; Gui L; Cai Y; Xin X; He X; Huang J
Front Oncol; 2021; 11():737986. PubMed ID: 34976797
[TBL] [Abstract][Full Text] [Related]
6. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
Konze KD; Ma A; Li F; Barsyte-Lovejoy D; Parton T; Macnevin CJ; Liu F; Gao C; Huang XP; Kuznetsova E; Rougie M; Jiang A; Pattenden SG; Norris JL; James LI; Roth BL; Brown PJ; Frye SV; Arrowsmith CH; Hahn KM; Wang GG; Vedadi M; Jin J
ACS Chem Biol; 2013; 8(6):1324-34. PubMed ID: 23614352
[TBL] [Abstract][Full Text] [Related]
7. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
[TBL] [Abstract][Full Text] [Related]
8. Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.
Abdalkader L; Oka T; Takata K; Sato H; Murakami I; Otte AP; Yoshino T
Pathology; 2016 Aug; 48(5):467-82. PubMed ID: 27311868
[TBL] [Abstract][Full Text] [Related]
9. EZH1/2 dual inhibitors suppress HTLV-1-infected cell proliferation and hyperimmune response in HTLV-1-associated myelopathy.
Koseki A; Araya N; Yamagishi M; Yamauchi J; Yagishita N; Takao N; Takahashi K; Kunitomo Y; Honma D; Araki K; Uchimaru K; Sato T; Yamano Y
Front Microbiol; 2023; 14():1175762. PubMed ID: 37378292
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors.
Shinohara H; Sawado R; Nakagawa M; Hattori A; Yamagata K; Tauchi K; Ito J; Kuwahara Y; Okuda T; Ogawa C; Kitabayashi I
Mol Ther Oncolytics; 2022 Dec; 27():14-25. PubMed ID: 36212776
[TBL] [Abstract][Full Text] [Related]
11. [Epigenetic aberrations in adult T-cell leukemia/lymphoma and development of a novel EZH1/2 inhibitor].
Yamagishi M
Rinsho Ketsueki; 2018; 59(4):432-438. PubMed ID: 29743404
[TBL] [Abstract][Full Text] [Related]
12. Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
Sircar A; Singh S; Xu-Monette ZY; Coyle KM; Hilton LK; Chavdoula E; Ranganathan P; Jain N; Hanel W; Tsichlis P; Alinari L; Peterson BR; Tao J; Muthusamy N; Baiocchi R; Epperla N; Young KH; Morin R; Sehgal L
Leukemia; 2023 Oct; 37(10):2094-2106. PubMed ID: 37598282
[TBL] [Abstract][Full Text] [Related]
13. A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma.
Kanduri M; Sander B; Ntoufa S; Papakonstantinou N; Sutton LA; Stamatopoulos K; Kanduri C; Rosenquist R
Epigenetics; 2013 Dec; 8(12):1280-8. PubMed ID: 24107828
[TBL] [Abstract][Full Text] [Related]
14. [Expression of MiR101 and EZH2 in Patients with Mantle Cell Lymphoma and Its Clinical Significance].
Lin YL; Zou ZK; Su HY; Huang YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):820-826. PubMed ID: 31204938
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2.
Wang X; Sehgal L; Jain N; Khashab T; Mathur R; Samaniego F
J Transl Med; 2016 Dec; 14(1):346. PubMed ID: 27998273
[TBL] [Abstract][Full Text] [Related]
16. Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
Dou F; Tian Z; Yang X; Li J; Wang R; Gao J
Drug Discov Ther; 2022 Dec; 16(6):297-299. PubMed ID: 36310058
[TBL] [Abstract][Full Text] [Related]
17. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
[TBL] [Abstract][Full Text] [Related]
18. Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.
Grindheim JM; Nicetto D; Donahue G; Zaret KS
Gastroenterology; 2019 May; 156(6):1834-1848. PubMed ID: 30689973
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex.
Hu G; Gupta SK; Troska TP; Nair A; Gupta M
Oncotarget; 2017 Oct; 8(46):80223-80234. PubMed ID: 29113297
[TBL] [Abstract][Full Text] [Related]
20. Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas.
Schümann FL; Groß E; Bauer M; Rohde C; Sandmann S; Terziev D; Müller LP; Posern G; Wienke A; Fend F; Hansmann ML; Klapper W; Rosenwald A; Stein H; Dugas M; Müller-Tidow C; Wickenhauser C; Binder M; Weber T
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
